| abstract |
The use is described of both (i) [1 R -[1α(Z),2β, 3β,5α]]-(+)-7-[5-[[(1,1ʹ-biphenyl)-4-yl]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt or solvate thereof and (ii) a thromboxane synthase inhibitor, either separately or in combination in the therapy or prophylaxis of occlusive vascular diseases in humans. n Pharmaceutical compositons containing both (i) and (ii) are also described. |